logo-loader
AIM:AVCT

Avacta Group PLC

Receive alerts
Market:
AIM
Market Cap:
£75.13 m
Price
42.13 GBX
Change
-2.60%
52 weeks high
48.00
52 weeks low
12.62

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.